SOPHiA GENETICS CLO reports initial share holdings
SOPHiA GENETICS SA filed an initial ownership report for Chief Legal Officer Daan Van Well, outlining his equity position in the company.
Rhea-AI Filing Summary
SOPHiA GENETICS SA filed an initial ownership report for Chief Legal Officer Daan Van Well, outlining his equity position in the company. He directly holds 261,922 ordinary shares, which includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time based on continued service. He also holds several option awards to buy ordinary shares, with exercise prices ranging from $3.29 to $18.00 per share and expiration dates between 2029 and 2035, providing long-term equity exposure but reflecting holdings rather than new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Van Well Daan
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 672,263 contracts (Direct);
Ordinary Shares — 261,922 shares (Direct)
Footnotes (5)
- F1. Includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 3,042 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 30,267 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 27,660 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 36,651 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
- F2. The share options are fully vested and exercisable.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
- F4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
- F5. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the SOPHiA GENETICS (SOPH) Form 3 filing show for Daan Van Well?
The Form 3 shows Chief Legal Officer Daan Van Well’s existing equity position, including direct ownership of 261,922 ordinary shares and multiple option grants and RSUs that vest over several years, giving him long-term exposure to SOPHiA GENETICS’ share performance.
What restricted stock units are reported for SOPHiA GENETICS CLO Daan Van Well?
The filing reports 97,620 ordinary shares issuable upon settlement of four RSU grants. These RSUs vest in monthly or quarterly installments from 2022 through 2028, with one grant vesting 50% on April 2, 2026, all conditioned on continued service with SOPHiA GENETICS.
What stock options does Daan Van Well hold in SOPHiA GENETICS?
Daan Van Well holds several share options to buy SOPHiA GENETICS ordinary shares, with exercise prices between $3.29 and $18.00 per share. These options cover different blocks of underlying shares and expire between 2029 and 2035, indicating long-dated equity incentives.
Are any of Daan Van Well’s SOPHiA GENETICS options fully vested and exercisable?
Yes. A footnote states that certain share options are fully vested and exercisable, meaning he can already purchase the underlying ordinary shares at the specified exercise prices, while other option grants continue to vest in installments over future years, subject to continued employment.
Does the SOPHiA GENETICS Form 3 indicate recent buying or selling by Daan Van Well?
The Form 3 primarily lists holdings of ordinary shares, RSUs, and options for Daan Van Well, rather than new open-market purchases or sales. It establishes his baseline ownership position as Chief Legal Officer, which future Forms 4 would update if transactions occur.
AI-generated analysis. How Rhea-AI works. Not financial advice.
